Glenn R. Mattes
Net Worth

Last updated:

What is Glenn R. Mattes net worth?

The estimated net worth of Mr. Glenn R. Mattes is at least $4,652,955 as of 16 May 2022. He owns shares worth $4,860 as insider, has earned $723,075 from insider trading and has received compensation worth at least $3,925,020 in TFF Pharmaceuticals, Inc..

What is the salary of Glenn R. Mattes?

Mr. Glenn R. Mattes salary is $654,170 per year as Pres, Chief Executive Officer & Director in TFF Pharmaceuticals, Inc..

How old is Glenn R. Mattes?

Mr. Glenn R. Mattes is 70 years old, born in 1955.

What stocks does Glenn R. Mattes currently own?

As insider, Mr. Glenn R. Mattes owns shares in one company:

Company Title Shares Price per share Total value
TFF Pharmaceuticals, Inc. (TFFP) Pres, Chief Executive Officer & Director 36,000 $0.14 $4,860

What does TFF Pharmaceuticals, Inc. do?

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

TFFP logo
TFFP
TFF Pharmaceuticals, Inc.
$0.14

Glenn R. Mattes insider trading

TFF Pharmaceuticals, Inc.

Mr. Glenn R. Mattes has made 6 insider trades between 2019-2022, according to the Form 4 filled with the SEC. Most recently he purchased 16,000 units of TFFP stock worth $76,480 on 16 May 2022.

The largest trade he's ever made was exercising 108,830 units of TFFP stock on 10 Nov 2020. As of 16 May 2022 he still owns at least 36,000 units of TFFP stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 16,000 $4.78 $76,480
Purchase
Common Stock 10,000 $7.1 $71,000
Sale
Common Stock 50,000 $2.5 $125,000
Option
Stock Options (Right to Buy) 50,000 $2.5 $125,000
Option
Common Stock 50,000 $2.5 $125,000
Option
Common Stock 40,000 $2.5 $100,000
Option
Stock Options (Right to Buy) 40,000 $2.5 $100,000
Sale
Common Stock 40,000 $2.5 $100,000
Option
Stock Options (Right to Buy) 40,000 $2.5 $100,000
Option
Common Stock 40,000 $2.5 $100,000
Sale
Common Stock 40,000 $2.5 $100,000
Option
Common Stock 30,000 $2.5 $75,000
Option
Stock Options (Right to Buy) 30,000 $2.5 $75,000
Sale
Common Stock 30,000 $2.5 $75,000
Sale
Common Stock 108,830 $2.5 $272,075
Option
Common Stock 108,830 $2.5 $272,075
Option
Stock Options (Right to Buy) 108,830 $2.5 $272,075
Sale
Common Stock 3,000 $17 $51,000
Purchase
Common Stock 10,000 N/A N/A

TFF Pharmaceuticals key executives

TFF Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: